These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 14746858)
1. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Kleeberg UR; Suciu S; Bröcker EB; Ruiter DJ; Chartier C; Liénard D; Marsden J; Schadendorf D; Eggermont AM; Eur J Cancer; 2004 Feb; 40(3):390-402. PubMed ID: 14746858 [TBL] [Abstract][Full Text] [Related]
2. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D; Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768 [TBL] [Abstract][Full Text] [Related]
3. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Garbe C; Radny P; Linse R; Dummer R; Gutzmer R; Ulrich J; Stadler R; Weichenthal M; Eigentler T; Ellwanger U; Hauschild A Ann Oncol; 2008 Jun; 19(6):1195-201. PubMed ID: 18281266 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216 [TBL] [Abstract][Full Text] [Related]
5. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H; Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809 [TBL] [Abstract][Full Text] [Related]
6. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group. De Mulder PH; Oosterhof G; Bouffioux C; van Oosterom AT; Vermeylen K; Sylvester R Br J Cancer; 1995 Feb; 71(2):371-5. PubMed ID: 7841054 [TBL] [Abstract][Full Text] [Related]
7. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A; Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144 [TBL] [Abstract][Full Text] [Related]
8. Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma. Vuoristo MS; Hahka-Kemppinen M; Parvinen LM; Pyrhönen S; Seppä H; Korpela M; Kellokumpu-Lehtinen P Melanoma Res; 2005 Aug; 15(4):291-6. PubMed ID: 16034308 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. Eggermont AMM; Rutkowski P; Dutriaux C; Hofman-Wellenhof R; Dziewulski P; Marples M; Grange F; Lok C; Pennachioli E; Robert C; van Akkooi ACJ; Bastholt L; Minisini A; Marshall E; Salès F; Grob JJ; Bechter O; Schadendorf D; Marreaud S; Kicinski M; Suciu S; Testori AAE Eur J Cancer; 2020 Jul; 133():94-103. PubMed ID: 32470710 [TBL] [Abstract][Full Text] [Related]
10. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. Hauschild A; Weichenthal M; Rass K; Linse R; Berking C; Böttjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Stein A; Näher H; Schadendorf D; Mohr P; Kaatz M; Tronnier M; Hein R; Schuler G; Egberts F; Garbe C J Clin Oncol; 2010 Feb; 28(5):841-6. PubMed ID: 20048184 [TBL] [Abstract][Full Text] [Related]
12. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Mocellin S; Lens MB; Pasquali S; Pilati P; Chiarion Sileni V Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008955. PubMed ID: 23775773 [TBL] [Abstract][Full Text] [Related]
14. Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma. Dréau D; Foster M; Hogg M; Swiggett J; Holder WD; White RL Oncol Res; 2000; 12(5):241-51. PubMed ID: 11417749 [TBL] [Abstract][Full Text] [Related]
15. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. Hauschild A; Weichenthal M; Balda BR; Becker JC; Wolff HH; Tilgen W; Schulte KW; Ring J; Schadendorf D; Lischner S; Burg G; Dummer R J Clin Oncol; 2003 Aug; 21(15):2883-8. PubMed ID: 12885805 [TBL] [Abstract][Full Text] [Related]
16. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). Fusi A; Collette S; Busse A; Suciu S; Rietz A; Santinami M; Kruit WH; Testori A; Punt CJ; Dalgleish AG; Spatz A; Eggermont AM; Keilholz U Eur J Cancer; 2009 Dec; 45(18):3189-97. PubMed ID: 19793643 [TBL] [Abstract][Full Text] [Related]
17. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy. McMasters KM; Egger ME; Edwards MJ; Ross MI; Reintgen DS; Noyes RD; Martin RC; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Sussman JJ; Davidson BS; Gershenwald JE; Hagendoorn LJ; Stromberg AJ; Scoggins CR J Clin Oncol; 2016 Apr; 34(10):1079-86. PubMed ID: 26858331 [TBL] [Abstract][Full Text] [Related]
18. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eggermont AM; Suciu S; Testori A; Kruit WH; Marsden J; Punt CJ; Santinami M; Salès F; Schadendorf D; Patel P; Dummer R; Robert C; Keilholz U; Yver A; Spatz A Eur J Cancer; 2012 Jan; 48(2):218-25. PubMed ID: 22056637 [TBL] [Abstract][Full Text] [Related]
19. Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. Rao UN; Ibrahim J; Flaherty LE; Richards J; Kirkwood JM J Clin Oncol; 2002 Apr; 20(8):2053-7. PubMed ID: 11956265 [TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Eggermont AM; Suciu S; Santinami M; Testori A; Kruit WH; Marsden J; Punt CJ; Salès F; Gore M; MacKie R; Kusic Z; Dummer R; Hauschild A; Musat E; Spatz A; Keilholz U; Lancet; 2008 Jul; 372(9633):117-126. PubMed ID: 18620949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]